Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy: prospective randomized comparison with ciprofloxacin

Lista Mateos, Fernando; Redondo, Cristina; Meilán, E.; García Tello, Ana; Fata Chillón, Fernando Ramón de; Angulo Cuesta, Javier

doi:10.1016/j.acuroe.2014.05.003

Home

dc.contributor.author	Lista Mateos, Fernando
dc.contributor.author	Redondo, Cristina
dc.contributor.author	Meilán, E.
dc.contributor.author	García Tello, Ana
dc.contributor.author	Fata Chillón, Fernando Ramón de
dc.contributor.author	Angulo Cuesta, Javier
dc.date.accessioned	2015-07-24T14:36:53Z
dc.date.available	2015-07-24T14:36:53Z
dc.date.issued	2014
dc.identifier.citation	Lista, F., Redondo, C., Meilán, E., García-Tello, A., de Fata, F. R., & Angulo, J. C. (2014). Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy: prospective randomized comparison with ciprofloxacin. Actas Urológicas Españolas (English Edition), 38(6), 391-396.	spa
dc.identifier.issn	02104806
dc.identifier.issn	16797980
dc.identifier.uri	http://hdl.handle.net/11268/4244
dc.description.abstract	Prostate biopsy is the standardized diagnostic method for prostate cancer. However, although there is not a standardized protocol, there are recommendations in order to reduce the incidence of complications. The objective of the present work is to assess the efficacy and safety of antibiotic prophylaxis in the prostate biopsy by comparing two antibiotic regimes: two doses of fosfomycin-trometamol 3 g (FMT) every 48 h with 10 doses of oral ciprofloxacin 500 mg every 12 h for 5 days.	spa
dc.language.iso	eng	spa
dc.subject.other	Biopsia de próstata	spa
dc.subject.other	Profilaxis antibiótica	spa
dc.title	Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy: prospective randomized comparison with ciprofloxacin	spa
dc.title.alternative	Eficacia y seguridad de fosfomicina-trometamol en la profilaxis de la biopsia transrectal de la próstata: estudio prospectivo aleatorizado comparativo con ciprofloxacino	spa
dc.type	article	spa
dc.description.impact	1.022 JCR (2014) Q4, 60/76 Urology & nephrology	spa
dc.identifier.doi	10.1016/j.acuroe.2014.05.003
dc.rights.accessRights	closedAccess	spa
dc.subject.uem	Urologia	spa
dc.subject.unesco	Medicina preventiva	spa
dc.description.filiation	UEM	spa
dc.peerreviewed	Si	spa